These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
888 related items for PubMed ID: 18261272
1. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia]. Wu DP, Yan LZ, Yang L, Chen SN, Wu XJ, Liang JY. Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272 [Abstract] [Full Text] [Related]
2. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H. Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943 [Abstract] [Full Text] [Related]
3. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Scholl S, Theuer C, Scheble V, Kunert C, Heller A, Mügge LO, Fricke HJ, Höffken K, Wedding U. Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718 [Abstract] [Full Text] [Related]
4. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, Creutzig U, Thiede C, Zwaan MC, van den Heuvel-Eibrink MM, Reinhardt D, Hiddemann W, Spiekermann K. Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003 [Abstract] [Full Text] [Related]
5. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Jiang A, Jiang H, Brandwein J, Kamel-Reid S, Chang H. Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989 [Abstract] [Full Text] [Related]
6. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia. Shamaa S, Laimon N, Aladle DA, Azmy E, Elghannam DM, Salem DA, Taalab MM. Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998 [Abstract] [Full Text] [Related]
7. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T. Clin Cancer Res; 2005 Feb 15; 11(4):1416-24. PubMed ID: 15746041 [Abstract] [Full Text] [Related]
8. [Correlation of NPM1, FLT3-ITD mutations with leukocyte count and myeloblasts percentage in AML patients with normal karyotype]. Su L, Li W, Cui JW, Tan YH, Yang Y, Liu XL, Yu P, Hu RP, Wang LL, Gao SJ. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun 15; 21(3):571-5. PubMed ID: 23815900 [Abstract] [Full Text] [Related]
9. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis]. Li L, Lyu XD, Mi RH, Ding J, Chen L, Wang Q, Yin QS, Hu JY, Fan RH, Wei XD. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun 15; 21(3):601-6. PubMed ID: 23815906 [Abstract] [Full Text] [Related]
10. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. How J, Sykes J, Gupta V, Yee KW, Schimmer AD, Schuh AC, Minden MD, Kamel-Reid S, Brandwein JM. Cancer; 2012 Dec 15; 118(24):6110-7. PubMed ID: 22736495 [Abstract] [Full Text] [Related]
11. C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics. Lu Y, Chen W, Chen W, Stein A, Weiss LM, Huang Q. Am J Hematol; 2010 Jun 15; 85(6):426-30. PubMed ID: 20513120 [Abstract] [Full Text] [Related]
12. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India. Ghosh K, Swaminathan S, Madkaikar M, Gupta M, Kerketta L, Vundinti B. Ann Hematol; 2012 Nov 15; 91(11):1703-12. PubMed ID: 22733614 [Abstract] [Full Text] [Related]
13. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics. Rezaei N, Arandi N, Valibeigi B, Haghpanah S, Khansalar M, Ramzi M. Turk J Haematol; 2017 Dec 01; 34(4):300-306. PubMed ID: 28294102 [Abstract] [Full Text] [Related]
14. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia. Park BG, Chi HS, Jang S, Park CJ, Kim DY, Lee JH, Lee JH, Lee KH. Ann Hematol; 2013 Apr 01; 92(4):451-7. PubMed ID: 23238897 [Abstract] [Full Text] [Related]
15. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. J Clin Oncol; 2010 Jun 01; 28(16):2739-47. PubMed ID: 20439648 [Abstract] [Full Text] [Related]
17. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. Dalal BI, Mansoor S, Manna M, Pi S, Sauro GD, Hogge DE. Clin Lymphoma Myeloma Leuk; 2012 Aug 01; 12(4):274-9. PubMed ID: 22481022 [Abstract] [Full Text] [Related]
19. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, German-Austrian Acute Myeloid Leukemia Study Group. N Engl J Med; 2008 May 01; 358(18):1909-18. PubMed ID: 18450602 [Abstract] [Full Text] [Related]